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Purpose: Melanoma represents an important public health problem, due to its high case-fatality 
rate. Identification of individuals at high risk would be of major interest to improve early diagnosis 
and ultimately survival. The aim of this study was to evaluate whether MC1R variants predicted 
melanoma risk independently of at-risk phenotypic characteristics.
Materials and methods: Data were collected within an international collaboration – the 
M-SKIP project. The present pooled analysis included data on 3,830 single, primary, sporadic, 
cutaneous melanoma cases and 2,619 controls from seven previously published case–control 
studies. All the studies had information on MC1R gene variants by sequencing analysis and on 
hair color, skin phototype, and freckles, ie, the phenotypic characteristics used to define the 
red hair phenotype.
Results: The presence of any MC1R variant was associated with melanoma risk independently 
of phenotypic characteristics (OR 1.60; 95% CI 1.36–1.88). Inclusion of MC1R variants in a risk 
prediction model increased melanoma predictive accuracy (area under the receiver-operating 
characteristic curve) by 0.7% over a base clinical model (P=0.002), and 24% of participants 
were better assessed (net reclassification index 95% CI 20%–30%). Subgroup analysis suggested 
a possibly stronger role of MC1R in melanoma prediction for participants without the red hair 
phenotype (net reclassification index: 28%) compared to paler skinned participants (15%).
Conclusion: The authors suggest that measuring the MC1R genotype might result in a 
benefit for melanoma prediction. The results could be a valid starting point to guide the 
development of scientific protocols assessing melanoma risk prediction tools incorporating 
the MC1R genotype.
Keywords: pooled analysis, genetic epidemiology, cutaneous melanoma, melanocortin 1 
receptor, pigmentation
Introduction
Incidence rates of malignant cutaneous melanoma (CM) continue to rise in most Euro-
pean countries, whereas in other countries, rates have become rather stable in recent 
years.1 CM still represents an important public health problem for its high case-fatality 
rate,2 and thus, identification of individuals at high risk of developing melanoma would 
be of major interest to improve early diagnosis and ultimately survival.
Known risk factors for CM include sun sensitivity, sun exposure, light hair and 
eye color, high number of melanocytic nevi, atypical nevi, and family history of 
melanoma.3–5 Knowledge of risk factors for CM is the basis for the development of 
risk prediction tools that may improve understanding and decision-making, leading 
to favorable behavior change and disease prevention.6–9 In addition to their clinical 
uses, these tools can assist in planning intervention trials and prevention strategies 
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that target particular risk groups.7–9 Clinical risk prediction 
models for CM have been previously reviewed:10 their dis-
crimination ranged from fair to very good (area under the 
receiver-operating characteristic curve [AUC] 0.62–0.86), 
comparable with those obtained for other cancers.10,11 The 
US Preventive Services Task Force considered the utility of 
these tools for population-based screening and concluded 
that the current evidence was insufficient to assess the bal-
ance of benefits and harms of visual skin examination by a 
primary care clinician or patient self-examination to screen 
for skin cancer of any type in adults.2,12 An accompanying 
editorial suggested that the Preventive Services Task Force 
statement should be viewed as an invitation to the scientific 
communities “to work together in executing well-designed 
studies . . . so future recommendations can be of greater 
public health benefit”.13 Since melanoma seems to be deter-
mined by complex interactions among host characteristics, 
environmental exposure, and genetic factors,14,15 the inclu-
sion and evaluation of genetic markers in risk models may 
be warranted and has been considered an important step for 
further development and testing of prediction tools before 
they can be used routinely with confidence.10
MC1R is the most important gene found to play a role 
in predisposition to sporadic CM, and its association with 
CM has been replicated and confirmed by meta-analyses 
and genome-wide association studies.16–21 The MC1R gene 
is located on chromosome 16q24.3 and is a key regulator 
of skin pigmentation.22 It is highly polymorphic in popula-
tions of European origin, with more than 200 coding region 
variants described to date23 and a prevalence of any MC1R 
variant of ~60% in healthy controls.16 Some of these variants 
have been shown to reduce receptor function,24–26 result in 
a quantitative shift of melanin synthesis from eumelanin to 
phaeomelanin,27 and determine the red hair (RH) phenotype, 
characterized by the co-occurrence of fair skin, RH, freck-
les, and ultraviolet (UV) radiation sensitivity (poor tanning 
response and solar lentigines).
Previous melanoma risk prediction models have 
included MC1R alongside base clinical risk factors15,28–31 
and reported slight improvement in risk prediction with 
MC1R inclusion. However, because of the strong relation-
ship between MC1R and phenotypic characteristics, their 
joint inclusion in the same model may generate biased 
estimates if the effect of MC1R on CM is mediated mainly 
by pigmentation. Therefore, before inclusion of MC1R in 
a risk prediction model in addition to phenotypic charac-
teristics, it should be demonstrated that MC1R has a direct 
effect on CM development through biological pathways that 
are independent of  pigmentation. There is some evidence 
for a wider biological role, as inherited variation at the 
MC1R locus has been reported to be associated with bet-
ter melanoma survival overall,32 but to reduce therapeutic 
benefit from treatment with BRAF inhibitors.33 A stronger 
role of MC1R variants in increasing melanoma risk in 
darker pigmented individuals has been suggested,16,18,34,35 
but the extent to which pigmentation and nonpigmentation 
pathways account for the association between MC1R and 
CM is still not clear.
Therefore, the aims of this study were 1) to decompose the 
total risk estimate of MC1R on CM into two different effects: 
one due to the nonpigmentation pathway (direct effect) and 
one due to the pigmentation pathway (indirect effect); and 2) 
to evaluate whether the inclusion of MC1R variants in risk-
prediction models increases their ability to predict CM in 
both the whole population and targeted subgroups of subjects 
with different phenotypic characteristics.
Materials and methods
Study population
Data were collected within the M-SKIP (melanocortin 
1 receptor, skin cancer, and phenotypic characteristics) 
project, described in detail elsewhere.36 Briefly, we gathered 
original individual data from studies on MC1R variants and 
phenotypic characteristics in patients with sporadic CM and 
nonmelanoma skin cancer and/or in healthy controls. Accord-
ing to familial melanoma definition,37,38 sporadic melanoma 
cases were defined as subjects with no more than one first-
degree relative or two any-degree relatives with melanoma. 
Since 2009, of 49 investigators contacted, 38 (78%) agreed 
to participate and sent their data along with a signed state-
ment declaring that their original study was approved by an 
ethics committee.
For the purpose of the present study, we excluded all the 
nonmelanoma skin cancer cases and included seven mela-
noma case–control studies18,30,34,39–43 according to inclusion 
criteria of the MC1R gene being sequenced and there being 
information available on hair color, skin phototype, and 
freckles, ie, the phenotypic characteristics used to define 
the RH phenotype. These phenotypic characteristics were 
those associated with MC1R genetic variants in our previous 
publication.44 The present study included data on 3,830 CM 
cases and 2,619 controls (Table 1).
Statistical analysis
A complete description of statistical analysis methods is 
reported in the Supplementary material.
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Mediation analysis
To estimate the independent contribution of MC1R variants 
on CM development, we performed a mediation analysis.45,46 
We decomposed the overall risk estimate for CM associated 
with MC1R into a direct effect due to the nonpigmentation 
pathway and an indirect effect due to the pigmentation path-
way. We estimated the direct effect of MC1R (any variant 
and the nine single common variants vs wild type [WT] on 
CM in the presence and in the absence of the RH phenotype 
(controlled direct effect [CDE]). Following our previous 
publication,44 RH phenotype was primarily defined as the 
presence of at least one of the characteristics of RH, freckles, 
and skin type I/II. Skin type is a measure of sun sensitivity of 
the skin and was defined in our study according to the known 
Fitzpatrick classification as type I (always burns, never tans), 
II (usually burns, tans minimally), III (sometimes mild burns, 
tans uniformly), and IV (never burns, tans easily). We also 
estimated the natural direct effect (NDE), which essentially 
averages CDE over the population and finally the indirect 
effect of MC1R mediated by RH phenotype (natural indirect 
effect [NIE]). Mediation analysis was separately applied 
to each of the seven studies, and ORs with 95% CIs were 
obtained for total effect (TE), NDE, NIE, and CDE using 
unconditional logistic regression models with the following 
covariates (when available) of age, sex, intermittent and 
chronic sun exposure, lifetime and childhood sunburns, fam-
ily history of melanoma, common nevi count, and presence 
of atypical nevi. Following the two-stage analysis approach, 
we pooled study-specific ORs with a random effects model. 
We calculated I2-values to assess the percentage of total 
variation across studies that was attributable to heterogeneity 
rather than to chance.
Model comparison
We tested the prediction ability to identify CM partici-
pants by adding MC1R variants to a clinical base predic-
tion model. Variables included in the base model were 
age, sex, sunburn, number of common nevi, and RH 
phenotype. These covariates were available in a subset 
of 4,390 (68%) participants from six studies. We used 
unconditional logistic regression to estimate the risk of 
CM according to the base clinical risk model and to the 
model including the MC1R gene, defined as the presence 
of any MC1R variants versus WT, the presence of only 
r variants and presence of at least one R variant versus 
WT, and the presence of each of the nine most common 
MC1R variants or rarer variants. R and r alleles have 
previously been defined according to their association 
with RH phenotype.17,22 We compared the predictive abil-
ity of the model with MC1R over the base clinical model 
by receiver-operating characteristic (ROC) curves, net 
reclassification improvement (NRI), and decision curve 
analysis. Analysis was carried out with the software SAS 
(version 9.2) and Stata (version 11.2).
Results
The main characteristics of the studies included are sum-
marized in Table 1. Three studies were performed in Italy, 
two in the US, one in the UK, and one in the Netherlands. 
All studies included more than 97% Caucasians. Two stud-
ies included hospital-based controls,30,31 and five recruited 
healthy controls. One study41 included an unpublished group 
of sporadic melanoma cases. The study approach, control 
group, and genetic analysis were the same described in the 
corresponding published paper.
Table 1 Description of the studies included in the analysis
Study Country Cases Controls Control 
typea
RH phenotypeb 
in controls
Available confoundersc
Kennedy et al39 The Netherlands 115 377 Hospital 210 (56%) Sun exposure, sunburn, common and atypical nevi
Landi et al34 Italy 163 169 Healthy 83 (49%) Sun exposure, sunburn, common nevi
Bishop et al40 UK 1567 469 Hospital 314 (67%) Sunburnd
Kanetsky et al18 USA 766 322 Healthy 262 (81%) Sun exposure, sunburn, atypical nevie
Menin et al41,f Italy 118 168 Healthy 70 (42%) Sunburn, common and atypical nevi
Ghiorzo et al42 Italy 236 355 Healthy 224 (63%) Sunburnd
Penn et al30 USA 865 759 Healthy 339 (45%) Sun exposure, sunburn, common nevi
Total 3,830 2,619 1,502 (57%)
Notes: aHealthy controls were population controls, friends or partners of cases, outpatients, or hospital personnel. bDefined as presence of red hair, freckles, or skin type 
I/II; cBeyond age and sex, which were available in all seven studies. Confounders with more than 20% of missing data not listed. Sun exposure includes separate information 
on chronic and intermittent sun exposure. dInformation on atypical nevi was also available, but with more than 20% of subjects with missing data. eNot included in risk model 
analysis because of missing data on common nevi. fIncluded an unpublished group of sporadic melanoma cases that were included in the present analysis. Study approach, 
control group, and genetic analysis were the same as described in Menin et al.41
Abbreviation: RH, red hair.
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Direct and indirect effects of MC1R on 
CM development
The OR (95% CI) for the TE of any MC1R variants on CM 
risk was 1.71 (1.46–2.00; I2=0; Figure 1). When decom-
posed, the risk was primarily due to the NDE, independent 
of phenotypic characteristics (OR 1.60; 95% CI 1.36–1.88; 
I2=0; Figure 1); the NIE, which would be dependent on 
the pigmentation pathway, was smaller (OR 1.07; 95% CI 
1.03–1.11; I2=0; Figure 1). When the CDE according to 
RH phenotype was examined, we found a direct, positive 
association between MC1R and CM in the absence of RH 
phenotype (OR 1.75; 95% CI 1.33–2.33; I2=0; Figure 2) 
and a smaller direct association between MC1R and CM 
in participants with the RH phenotype (OR 1.50; 95% CI 
1.19–1.89; I2=37%; Figure 2).
Looking at each of the nine most common MC1R variants 
(Table S1), we still found for all of them larger NDE than 
NIE, with significant NDE found for the R variants R142H, 
R151C, R160W, and D294K (ranging from OR 2.22; 95% CI 
1.33–3.71 to OR 3.55; 95% CI 1.21–10.47) and significant 
NIE found only for the R variant R151C (OR 1.18; 95% 
CI 1.00–1.39). Furthermore, CDE was higher for non-RH-
phenotype subjects than for RH-phenotype subjects for the 
most common variants (allele frequency ≥1.5%), while it was 
opposite for the three rarer MC1R variants D84E, R142H, 
and I155T (Table S1).
Risk models for CM prediction
Table 2 reports the ORs and 95% CIs for variables included 
in the base clinical risk model and for MC1R variants. Hav-
ing more than 30 common nevi and RH phenotype increased 
CM risk in our population (Table 2). Independent of other 
risk factors, carriers of any MC1R variant had a higher risk 
of CM than noncarriers (OR 1.63; 95% CI 1.40–1.90). The 
OR slightly decreased when the analysis was restricted to 
RH participants, while it increased for non-RH participants 
(Table 2). When we considered a distinction between MC1R 
r and R variants, in comparison with WT, carriers of at least 
one R variant had a higher risk of CM (OR 2.08; 95% CI 
1.76–2.46) than carriers of only r variants (OR 1.24; 95% CI 
1.04–1.47). For RH participants, carrying only MC1R r vari-
ants did not increase CM risk, while the risk was increased 
for carriers of MC1R R variants. By contrast, both MC1R r 
and R variants were associated with a higher risk of CM in 
participants with the non-RH phenotype (Table 2). Similar 
results were found looking at each of the nine MC1R variants 
separately (Table S2).
The clinical risk model yielded an AUC of 0.706 (95% 
CI 0.691–0.721; Table S3). The model including any MC1R 
variant showed slightly greater discrimination, with an AUC 
of 0.713 (95% CI 0.698–0.728; P=0.002) and an NRI of 24% 
(95% CI 20%–30%). Differentiation between r and R vari-
ants and considering each single variant further increased 
diagnostic accuracy by 1.5% and 1.9%, respectively, over 
the base clinical risk model, with an NRI of 37% (95% CI 
32%–43%) and 34% (28%–39%), respectively. Subgroup 
analysis restricted to participants with the non-RH phenotype 
revealed that MC1R improved the AUC by 1.8% (from 0.678 
to 0.696, P=0.0008; Figure 3; Table S3), suggesting a stronger 
role of MC1R in melanoma prediction for darker pigmented 
participants compared to RH participants. The NRI due to 
MC1R inclusion for participants with a non-RH phenotype 
was 28% (95% CI 19%–37%), while it was 15% (95% CI 
9%–22%) for RH participants. The addiction of separate 
information on r and R MC1R variants and on single specific 
variants obtained a better model performance for both RH 
and non-RH participants. Decision curves showed a small 
increase in net benefit of MC1R testing for non-RH partici-
pants over almost the entire range of threshold probabilities 
(Figure S1), with an average increase in net benefit of 0.003 
for the model with any MC1R variant and 0.005 for the model 
with r or R MC1R variant over the base clinical model.
Sensitivity analysis on a subset of 2,472 (38%) par-
ticipants from four studies with additional information on 
atypical nevi provided similar results (not shown): having 
more than 30 common nevi, RH phenotype, and atypical 
nevi increased CM risk. In this sensitivity analysis, MC1R 
variants increased CM risk in non-RH participants, but not 
in RH participants. Sensitivity analysis with different defini-
tions of RH phenotype provided similar results (not shown).
Discussion
Our pooled analysis showed that the presence of any MC1R 
variant had a direct effect on CM, conferring a 60% higher 
risk to carriers versus noncarriers. The pigmentation-
mediated effect of MC1R on CM was smaller with any 
MC1R variant and each of the nine most common MC1R 
variants. This result confirms and expands the previous sug-
gestion16–18,34 of the existence of a nonpigmentation pathway 
leading MC1R to CM development. Here, we give for the first 
time an estimate of the magnitude of total effect explained 
by each of the two (pigmentation and nonpigmentation) 
pathways. Recent studies and reviews47 have implicated 
MC1R signaling in a number of key biological pathways 
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Figure 1 Forest plot for NDE, NIE, and TE of any MC1R variant on melanoma risk.
Notes: CDE estimates the direct effect of MC1R on melanoma when the mediator is controlled at level 0 (absent) or 1 (present) uniformly in the population, NDE essentially 
averages CDE over the population, NIE estimates the indirect effect of MC1R mediated by RH phenotype, and TE is the overall melanoma risk estimate for MC1R carriers 
and in each study is the product of NDE and NIE.
Abbreviations: CDE, control direct effect; NDE, natural direct effect; NIE, natural indirect effect; PY, publication year; RH, red hair; SOR, summary OR; TE, total effect.
????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????? ???????? ???? ???? ????
involved in cell-cycle control,48 apoptosis,49 and activation 
of DNA-repair mechanisms and antioxidant defenses.50 
Production of pheomelanin pigments seems associated with 
increased oxidative DNA damage compared with synthesis of 
eumelanins.51 Further evidence for pheomelanin-associated 
increased cellular oxidative stress was obtained in studies of 
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mice carrying a loss-of-function mutation of the Mc1r gene, 
which provided evidence in support that the pheomelanin-
pigment pathway produces UV-independent carcinogenic 
contributions to melanomagenesis.52 Another recent study53 
found a role of germ-line MC1R variants in influencing the 
somatic mutational landscape of melanoma, with an expected 
Figure 2 Forest plot for control direct effect of any MC1R variant on melanoma risk according to RH phenotype.*
Notes: *Defined as presence of red hair, freckles, or skin type I/II. Control direct effect estimates the direct effect of MC1R on melanoma when the mediator is controlled 
at level 0 (absent) or 1 (present) uniformly in the population.
Abbreviations: PY, publication year; RH, red hair; SOR, summary OR.
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????? ?????? ??? ???? ???? ????
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Table 2 ORs with 95% CIs for melanoma risk according to a base clinical model and the same model with inclusion of MC1R variants
All participants (n=4,390) RH participants (n=2,654) Non-RH participants (n=1,736)
Base model Base model +  
MC1R
Base model Base model +  
MC1R
Base model Base model +  
MC1R
Agea 0.97 (0.94–1.00) 0.97 (0.94–1.00) 0.96 (0.92–0.99) 0.96 (0.92–0.99) 0.99 (0.94–1.04) 0.99 (0.94–1.04)
Sex
Male 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Female 1.01 (0.89–1.16) 1.03 (0.91–1.18) 0.92 (0.77–1.09) 0.92 (0.77–1.10) 1.18 (0.96–1.45) 1.23 (1.00–1.52)
Sunburn
None 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Any 1.15 (0.98–1.35) 1.11 (0.94–1.30) 1.16 (0.94–1.43) 1.13 (0.91–1.39) 1.13 (0.88–1.47) 1.08 (0.84–1.41)
Common nevi
≤30 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
>30 3.37 (2.90–3.92) 3.40 (2.92–3.96) 3.46 (2.86–4.18) 3.47 (2.87–4.20) 3.25 (2.53–4.16) 3.30 (2.57–4.24)
Phenotype
Non-RH 1.00 (reference) 1.00 (reference) – – – –
RH 1.64 (1.43–1.88) 1.52 (1.32–1.75) – – – –
MC1R
None – 1.00 (reference) – 1.00 (reference) – 1.00 (reference)
Any variant – 1.63 (1.40–1.90) – 1.55 (1.25–1.92) – 1.76 (1.41–2.19)
Only r variants – 1.24 (1.04–1.47) – 1.07 (0.84–1.37) – 1.45 (1.14–1.86)
≥1 R variant – 2.08 (1.76–2.46) – 1.92 (1.53–2.41) – 2.25 (1.73–2.92)
Notes: aPer 5-year increase. Significant ORs are in bold. All models are adjusted for variables included in the table + study center. Two separate models were created for 1) 
any MC1R variant vs wild type and 2) only r variants and ≥1R variant vs wild type. R and r alleles were defined basing on their stronger or weaker association with the RH 
phenotype for the most common variants44,67–70 and on likely pathogenicity using the algorithm proposed by Davies et al32 for the less common variants.
Abbreviation: RH, red hair.
Figure 3 ROC curve comparison between base clinical model and the same model with inclusion of MC1R variants for patients with no RH phenotype.*
Notes: (A) MC1R defined as the presence or absence of any MC1R variant and (B) as no MC1R variant, only r variants, and ≥1 R variants. *Non-RH patients defined as those 
without RH and freckles and with skin type III/IV. R and r alleles were respectively defined basing on their stronger or weaker association with the RH phenotype for the 
most common variants44,67–70 and on likely pathogenicity using the algorithm proposed by Davies et al32 for the less common variants.
Abbreviations: RH, red hair; ROC, receiver-operating characteristic.
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higher number of somatic C>T mutations in carriers of R 
alleles than those without R alleles. In this respect, it is worth 
noting that although the most relevant UV radiation-induced 
mutations are C>T transitions, highly recurrent mutations 
in key melanoma-driver genes, such as the V600E mutation 
in BRAF, are non-C>T changes. Importantly, significant 
increases in the rate of non-C>T changes, some of which 
might depend on oxidative DNA damage, have also been 
found in R allele carriers compared with noncarriers.53,54 
Accordingly, associations of MC1R and genes frequently 
mutated in melanoma, such as BRAF or TERT, have been 
reported.55–57
We found that MC1R slightly improved risk prediction 
accuracy over a base clinical model, especially for non-RH 
participants: CM predictive accuracy increased by 1.8% and 
the CM risk of 28% of participants was better assessed. If a 
distinction is used in the model to differently score r and R 
variants, the benefit for the whole population increased from 
24% of participants correctly reclassified with just presence/
absence of MC1R variants to 37% of participants correctly 
reclassified with separate information on r and R variants. 
Distinction between r and R alleles, however, was more 
apparent for RH than for non-RH participants. In the study 
by Cust et al,15 the R variants were responsible for most of 
the improvement in risk prediction, but separate analysis for 
RH and non-RH participants was not performed.
Previous melanoma risk prediction models have included 
MC1R with base clinical risk factors.15,28–30 Whiteman and 
Green28 did not report on predictive ability. Stefanaki et al29 
found no improvement in AUC with the addition of eight 
 melanoma-associated single-nucleotide polymorphisms 
(SNPs) to the base model. Both Cust et al15 and Penn et al30 
reported slight improvement in AUC with the inclusion of 
MC1R. However, no previous paper has reported separate 
results according to fairer or darker phenotypic characteris-
tics. This point seems in fact extremely important, because 
MC1R seems to have a stronger role in non-RH participants 
in both the present paper and in previously published strati-
fied analyses.16,18,34 A more precise risk assessment, therefore, 
in participants with no RH, no freckles, and skin type III/
IV could potentially change individual clinical follow-up 
schedules and perhaps UV-exposure behavior and indoor 
tanning habits.
The application of risk prediction tools in cancer screen-
ing has been widely discussed. In particular, there have 
been concerns on the impact of genetic screening in clinical 
decision-making. For example, in a previous review,58 genetic 
screening was discussed using commercially  available SNP 
panel tests in prostate cancer. Conclusions were that the 
investigated SNP panels had poor discriminative ability and 
clinical validity. In our study, adding the MC1R genotype 
resulted in a small yet significant improvement in predictive 
ability over the clinical model and a substantial change in 
the NRI, and it is worth noting that this improvement was 
based on a single gene, while risk indices for both prostate 
and breast cancer require several genetic markers to produce 
increases of similar magnitude.59–62 Decreasing genotyping 
costs and increasing use of genetic testing is making it more 
feasible to incorporate genetic risk factors into clinical risk 
prediction tools, and limiting testing to the non-RH partici-
pants with no other risk factors may result in a cost-effective 
strategy via better allocation of resources. However, transla-
tion into routine clinical practice requires several additional 
steps,63,64 and new studies are needed in order better to assess 
the clinical utility of these models, taking also into account 
the small increase in net benefit observed in our decision 
curve analysis.
Our study has several strengths. We quantified for the 
first time the amount of total effect of MC1R on CM due 
to pigmentation and nonpigmentation pathways. Previous 
stratified analyses, including ours,16 have already suggested 
that the effect of MC1R was stronger in darker pigmented 
participants; however, stratified analyses are not conclu-
sive, especially in the presence of genotype–phenotype 
 interaction.46,65 Precise and powerful quantification of the 
effect of the two pathways was only feasible in the present 
analysis after inclusion of new studies.30,40,41 The large sample 
and international collaborative nature of the M-SKIP project 
make it possible to assess various populations and ances-
tries, thus providing results that are robust and consistent 
in different geographical areas. We were also able to create 
different predictive models according to the RH and non-RH 
phenotypes, which was not possible in previous studies. In 
our centralized statistical analysis, we were able to take into 
account all the available confounders, with a homogeneous 
plan of analysis and definition of covariables.
Heterogeneity among different populations is a possible 
limitation of our study; therefore, this tool may require adjust-
ments before being applicable to each specific population.10 
However, it is not easy to develop a good and precise tool 
for each population due to the lack of power of single stud-
ies. Moreover, we did not observe any heterogeneity in risk 
estimates for MC1R and CM, suggesting that information on 
MC1R improves CM risk prediction in different populations 
of European origins. Following our previous publication,44 
RH participants were defined as participants with either 
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RH, freckles, or skin type I/II, and we are aware that other 
definitions may modify the results. However, in a sensitivity 
analysis using RH defined as a score obtained from multiple 
correspondence analysis,44 the results were similar. Pheno-
type misclassification is a possibility, although a previous 
study reported a good correlation between self-defined skin 
pigmentation and measured melanin density.66 In order to 
minimize phenotype misclassification, we performed a sen-
sitivity analysis that included only extreme categories of the 
RH phenotype.5 Although this analysis was underpowered, 
we observed similar risk estimates to those reported for 
the main analysis in the present paper (results not shown). 
Finally, it should be noted that our analyses were performed 
on sporadic melanoma cases, and thus, generalization to 
familial melanoma is not appropriate.
Conclusion
We found a direct role of MC1R in melanoma risk inde-
pendently of RH phenotype and demonstrated that add-
ing the MC1R genotype to classical clinical risk factors 
results in a benefit for CM prediction. A change in clinical 
follow-up schedules and UV exposure and sun protection 
habits of identified at-risk individuals might favor early 
melanoma diagnosis and prevention. The application of 
risk prediction tools in cancer screening has been contro-
versial, because of concerns on their impact in clinical 
decision-making. Our results could be a valid starting 
point to guide the development of scientific protocols 
assessing melanoma risk prediction tools incorporating 
the MC1R genotype, ideally with a prospective design 
and cost–benefit evaluation.
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